Exec Chat: Miach Orthopaedics Bullish On BEAR For Repairing, Not Replacing, Torn ACLs

Medtech Insight spoke with Martha Shadan, CEO of Miach Orthopaedics, about the company’s marketing efforts for its US FDA-cleared BEAR implant for treating anterior cruciate ligament (ACL) tears, ongoing clinical trials, plans for the rest of the year, and highlights from the AAOS 2022 event.

Kneeinjury
• Source: Alamy

Miach Orthopaedics’ CEO Martha Shadan expressed excitement about surgeons’ uptake of its now commercially available bio-engineered Bridge-Enhanced ACL Restoration, BEAR implant, designed to get patients with anterior cruciate ligament tears back on their feet and back to their sports faster post-surgery compared with standard ACL reconstruction.

Since Miach launched the BEAR implant this January, after receiving US Food and Drug Administration de novo clearance in...

Welcome to Medtech Insight

Create an account to read this article

More from Orthopedics

More from Device Area